High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

NCT07182708 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)
EGFR Activating Mutation
Resectable Lung Non-Small Cell Carcinoma

Interventions

DRUG: Firmonertinib Mesilate Tablets
DRUG: Bevacizumab injection

Sponsor

Peking University Cancer Hospital & Institute